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Glycophosphatidylinositol-anchored proteins (GPI-
APs) play essential roles in physiology, but their
biogenesis and trafficking have not been systemati-
cally characterized. Here, we took advantage of the
recently available haploid genetics approach to
dissect GPI-AP pathways in human cells using prion
protein (PrP) and CD59 as model molecules. Our
screens recovered a large number of common and
unexpectedly specialized factors in the GPI-AP path-
ways. PIGN, PGAP2, and PIGF, which encode GPI
anchor-modifying enzymes, were selectively isolated
in the CD59 screen, suggesting that GPI anchor
composition significantly influences the biogenesis
of GPI-APs in a substrate-dependent manner.
SEC62 and SEC63, which encode components of
the ER-targeting machinery, were selectively recov-
ered in the PrP screen, indicating that they do not
constitute a universal route for the biogenesis of
mammalian GPI-APs. Together, these comparative
haploid genetic screens demonstrate that, despite
their similarity in overall architecture and subcellular
localization, GPI-APs follow markedly distinct
biosynthetic and trafficking pathways.INTRODUCTION
In eukaryotic cells, membrane proteins are usually manufactured
in the ER, where they fold into native conformations and receive
posttranslational modifications (Walter and Ron, 2011). With the
exception of ER-localized molecules, these proteins are ex-
ported from the ER and transported to their destined organelles
(Bonifacino and Glick, 2004). Many mediators of membrane pro-
tein biogenesis and trafficking were identified by powerful ge-
netic screens using model organisms, mainly the budding yeast
Saccharomyces cerevisiae (Novick et al., 1980; Bankaitis et al.,
1986). While these mediators are well conserved, membrane
pathways in mammalian cells are significantly more complex,Ceoften exhibiting unique features not found in classic model
organisms (Bryant et al., 2002).
Despite intensive efforts, genome-wide genetic screens in
mammalian cells have been impeded by one critical barrier—
the diploidy or polyploidy of virtually all cultured mammalian
cell lines. In these cultured cells, random mutagenesis usually
only inactivates one copy of a gene, which seldom leads to
obvious phenotypes at the cellular level. RNAi has been instru-
mental in unraveling mammalian gene functions but is limited
by incomplete gene silencing and substantial off-target effects
(Sigoillot et al., 2012). Recently, multiple mammalian haploid
cell lines, including tumor cells and pluripotent stem cells, were
isolated (Kotecki et al., 1999; Carette et al., 2011b; Yang et al.,
2012; Li et al., 2012; Leeb and Wutz, 2011). Given that haploid
cells contain only one copy of each gene, single mutations can
abolish the expression of the gene and result in a null genotype.
As a result, genetic screens can be performed in these haploid
cells in a similar way as in yeasts.
In this work, we took advantage of the haploid genetics system
to dissectmembrane protein biogenesis and trafficking in human
cells. We focused on a class of membrane-bound molecules—
the glycophosphatidylinositol-anchored proteins (GPI-APs).
Constituting 10%–20% of membrane proteins, GPI-APs play
essential roles in a range of biological processes (Nozaki et al.,
1999; Orlean and Menon, 2007). Imbalances in their activities
are associated with major forms of human disorder such as neu-
rodegeneration and immunodeficiency (Fujita and Kinoshita,
2012; Bonnon et al., 2010; Mayor and Riezman, 2004). After
translocation into the ER lumen, the protein moiety of the GPI-
AP is covalently conjugated to the GPI anchor, a glycolipid struc-
ture spanning the lumenal/exoplasmic leaflet of the membrane
bilayer. Subsequently, the mature GPI-AP is targeted to the
cell surface where it remains attached to the membrane through
its C-terminal GPI anchor (Orlean and Menon, 2007; Paulick and
Bertozzi, 2008).
Using haploid genetics, we dissected the biosynthesis and
trafficking of two unrelated human GPI-APs—the prion protein
(PrP) and the immune molecule CD59. PrP is well known for its
implications in prion diseases (Prusiner et al., 1998), whereas
CD59 is a key regulator of complement-mediated cell lysis (Pet-
tigrew et al., 2009; Yamashina et al., 1990). Our screens recov-
ered a large number of factors required for both the PrP andll Reports 11, 1727–1736, June 23, 2015 ª2015 The Authors 1727
Figure 1. Haploid Genetic Screen of the PrP
Pathway
(A) Diagram showing the haploid genetic screen of
the PrP pathway using the mutant HAP1 cell
library.
(B) Mutant HAP1 cells were labeled with anti-PrP
antibodies and APC-conjugated anti-mouse anti-
bodies. FACS was used to collect cells with the
lowest fluorescence signal. After the third round of
sorting, cells were divided into two populations—
dim and dark—according to their fluorescence
intensity. The dark population contained cells with
log fluorescence intensity less than 10, while the
dim population contained cells with log fluores-
cence intensity between 10 and 500. Genomic
DNA samples from the dark and dim populations
were combined in equal amounts, and retroviral
gene-trap insertions were mapped by deep
sequencing.CD59 pathways, most of which are involved in the synthesis of
the GPI anchor. Unexpectedly, we isolated several genes that
impact only one GPI-AP pathway but not the other. PIGN,
PGAP2, and PIGF, which encode GPI anchor-modifying en-
zymes, were required for the CD59 pathway but not for the PrP
pathway. Thus, GPI anchor composition can significantly influ-
ence the biogenesis of GPI-APs in a substrate-dependent
manner. Sec62p and Sec63p (yeast homologs of SEC62 and
SEC63), on the other hand, belong to the SRP-independent ER
targeting machinery that is thought to regulate the entire class
of GPI-APs in yeasts (Ast et al., 2013). However, we observed
that in human cells SEC62 and SEC63 are dispensable for the
biogenesis of all GPI-APs we examined except PrP, indicating
that the SEC62-SEC63 pathway is not a universal requirement
for GPI-APs. We further demonstrated that the signal sequence
of PrP determines the engagement in the SEC62-SEC63
pathway. Together, these comparative haploid genetic screens
demonstrate that, despite their similarity in overall architecture
and subcellular localization, GPI-APs follow markedly distinct
biosynthetic and trafficking pathways.
RESULTS
Haploid Genetic Screen of the PrP Pathway
We built a mutant haploid cell library in which the haploid HAP1
cells were randomly mutagenized by gene-trap retroviral inser-1728 Cell Reports 11, 1727–1736, June 23, 2015 ª2015 The Authorstions (Figure 1A). Gene-trap insertions
create null versions of trapped genes by
introducing a splice acceptor site within
an intron or by causing frameshift muta-
tions within an exon (Carette et al.,
2009). We used fluorescence-activated
cell sorting (FACS) to enrich for mutant
HAP1 cells that exhibited strongly
reduced surface expression of PrP (Fig-
ure 1B). Since cell surface targeting
represents the terminal step of the GPI-
AP pathway, this quantitative sortingapproach is expected to interrogate the entire biosynthetic and
trafficking pathway of a GPI-AP. After three rounds of sorting,
surface expression of PrP was largely abrogated in the enriched
mutant cells (Figure 1B). We divided the sorted mutant cells into
two populations consisting of dim cells or dark cells (Figure 1B),
aiming to prevent downstream sequencing reactions from being
overwhelmed by a small number of highly enriched genes.
Gene-trap retroviral insertions in the enriched HAP1 popula-
tion were mapped by deep sequencing and compared with
those in unselected mutagenized HAP1 cells (control popula-
tion) to identify genes enriched for mutagenic gene-trap inser-
tions. The significance of each gene hit was calculated using
the Fisher’s exact test and ranked according to the p value
(Figure 2; Table S1). As expected, one of the most statistically
significant hits identified in the screen was PRNP, the gene
that encodes the PrP protein (Figure 2). In addition, the screen
recovered a large number of other factors, including virtually
all of the enzymes known to be essential to the synthesis of
the GPI anchor (Figure 2). Localized to the ER or the Golgi,
these GPI synthesis enzymes sequentially build the GPI an-
chor on the membrane and ultimately transfer it to the protein
moiety to form the mature GPI-AP (Ferguson et al., 2009; To-
kunaga et al., 2014). Identification of PRNP and the known
essential GPI synthesis genes indicates that the haploid
screen is strikingly exhaustive. Moreover, no new genes en-
coding potential GPI synthetic or attachment factors were
Prp Screen
Figure 2. Hits from the Haploid Genetic Screen of the PrP Pathway
The y axis represents the log10 of p values for the gene hits in the selected
population as compared to a published unselected control (Jae et al., 2013)
using Fisher’s exact test. We set a p value cutoff of 1 3 105 to account for
multiple hypothesis testing. In addition, for genes with a p value less significant
than 1 3 1010, we only considered genes as hits if they also had strong bias
for sense-strand intron insertions. The x axis represents the chromosomal
positions of the genes. Circle size is scaled according to the number of unique
inactivating gene-trap insertions a gene received. Circles are colored ac-
cording to functional groups. Dashed line indicates the cutoff of significance.
Figure 3. Hits from the Haploid Genetic Screen of the CD59 Pathway
The y axis represents the log10 of p values for the gene hits as described in
Figure 2. The x axis represents the chromosomal positions of the genes. Circle
size is scaled according to the number of unique inactivating gene-trap in-
sertions a gene received. Circles are colored according to functional groups.
Dashed line indicates the cutoff of significance.recovered, suggesting that the haploid genetic screen has
reached saturation.
Haploid Genetic Dissection of the CD59 Pathway
and Comparison with the PrP Screen
To identify common and disparate components of GPI-AP path-
ways, we next performed a second haploid genetic screen to
identify genes involved in the biogenesis of CD59, a GPI-AP un-
related to PrP (Yamashina et al., 1990; Ho¨chsmann et al., 2014).
Mutant cells deficient in CD59 surface expression were enriched
using the same FACS sorting strategy as in the PrP screen, and
their gene-trap insertions were mapped by deep sequencing. As
expected, this haploid genetic screen identified the CD59 gene
itself, as well as all the genes known to be critical to GPI anchor
synthesis (Figure 3; Table S1).
In order to compare the relative importance of individual hits
between the CD59 and PrP screens, unique gene-trap inser-
tions in each dataset were normalized using the quantile
method such that the numbers of unique mutagenic insertions
could be compared across populations. The normalized data-
sets were then hierarchically clustered to generate a heatmap
(Figure 4A). As revealed by the heatmap, most of the genes
common to both the PrP and CD59 pathways encode the
essential components of the GPI synthesis and attachment ma-
chinery (Figure 4A). Interestingly, we discovered that several
genes, including PIGN, PGAP2, PIGF, SEC62, SEC63, and
SPPL3, were only required for one GPI-AP pathway but not
the other (Figure 4B).
Several genes implicated in GPI anchor modifications,
including PIGG, PGAP5, PIGY,DPM2 and PIGZ, were not recov-
ered in our haploid genetic screens. PIGG and PGAP5 areCeinvolved in the addition and removal, respectively, of a side-
chain modification on the second mannose of the GPI anchor
(Shishioh et al., 2005; Fujita et al., 2009). PIGY and DPM2, on
the other hand, represent protein components of the GPI-N-ace-
tylglucosaminyltransferase (Watanabe et al., 1998). Finally, PIGZ
encodes an enzyme that transfers a fourth mannose to the
maturing GPI anchor (Orlean and Menon, 2007). The absence
of these genes in our screens suggests that they do not consti-
tute central components of the GPI anchor biosynthetic
pathway. In line with this notion, the expression of PIGZ appears
to be restricted to neuronal and colon tissues, influencing only
certain tissue-specific GPI-APs (Taron et al., 2004).
Together, these data demonstrate that GPI-AP pathways
involve both common and substrate-specific factors.
GPI Anchor Modifications Have Disparate Effects
on GPI-AP Pathways
One of the GPI anchor synthesis genes identified in both the PrP
and CD59 screens is PIGP, which encodes a component of the
GPI-N-acetylglucosaminyltransferase complex catalyzing the
transfer of N-acetylglucosamine (GlcNAc) to phosphatidylinosi-
tol (PI) (Figure S1A) (Orlean and Menon, 2007). We next used
CRISPR/Cas9 to delete the PIGP gene in HAP1 cells. We
observed that the surface expression of both PrP and CD59
was strongly reduced (Figure S1B), confirming the results of
the haploid genetic screens. These data also indicate that the
targeting of mature PrP and CD59 to the cell surface is strictly
dependent on the GPI anchor. The C-terminal hydrophobic
GPI-conjugation sequence may also associate with membrane
bilayers (Ast et al., 2013), but the conjugation sequence itself is
clearly inadequate for properly targeting GPI-APs to the cell
surface.
Three GPI anchor synthesis genes—PIGN, PGAP2, and
PIGF—were only recovered in the CD59 screen. This is an unex-
pected finding because modifications conferred by these genell Reports 11, 1727–1736, June 23, 2015 ª2015 The Authors 1729
AB
Figure 4. Comparison of the Hits from the
PrP and CD59 Screens
(A) Heatmap showing the gene hits from the PrP
and CD59 screens. Unique gene-trap insertions of
gene hits were quantile normalized and clustered
using the Euclidean distance metric. Dashed tur-
quoise lines represent the sample mean, and the
solid turquoise lines represent each hit’s number of
unique insertions relative to the sample mean.
(B) Common and disparate genes recovered from
the PrP and CD59 screens.products are thought to constitute conserved steps of GPI an-
chor synthesis (Orlean and Menon, 2007; Fujita and Kinoshita,
2012). Next we used CRISPR/Cas9 to knock out the PIGN
gene, which encodes an enzyme that transfers a phosphoetha-
nolamine (EtNP) to the first mannose of the GPI anchor (Fig-
ure S1A) (Hong et al., 1999). We observed that the surface
expression of CD59, but not that of PrP, was markedly
decreased in the PIGN null HAP1 cells (Figure S1C), confirming
the results of the haploid genetic screens. Next we sought to
expand this finding by examining CD55 and CD109, another
two GPI-APs localized to the cell surface (Burge et al., 1981;
Nicholson-Weller et al., 1981; Bizet et al., 2011). We observed
that the surface level of CD109 was markedly reduced in PIGN
null cells, whereas the surface expression of CD55 was not
significantly affected (Figure S2).
Next, we generated PGAP2 knockout cells using CRISPR/
Cas9 and examined how the mutation influences GPI-APs.
PGAP2 encodes an enzyme that is required for re-acylation at
the sn2 position with a saturated acyl chain (Hong et al., 1999).
We observed that the surface level of CD59 was markedly
reduced in PGAP2 null cells, whereas the surface expression
of PrP remained intact (Figure S2), which is consistent with the
results of the haploid genetic screens. Further analysis showed
that the surface levels of both CD55 and CD109 were also signif-
icantly decreased in PGAP2 null cells (Figure S2). Interestingly,
the GPI-APs that are sensitive to PGAP2 knockout are different
from those sensitive to PIGN knockout, suggesting that GPI
modifications have markedly distinct effects on individual GPI-
AP pathways.
Next, we further characterized how GPI anchor modifications
affect the surface targeting of GPI-APs. Here we focused on the
trafficking of CD59 in PGAP2 null cells. Interestingly, while
PGAP2 knockout strongly reduced the surface level of CD59,
the total expression level of CD59 remained largely unchanged
(Figure S3A). Immunostaining showed that CD59 was retained
in intracellular compartments in PGAP2 null cells (Figure S3B).
In contrast, CD59 was found mainly on the cell surface in WT1730 Cell Reports 11, 1727–1736, June 23, 2015 ª2015 The Authorscells, consistent with the flow cytometry
data (Figure S2). In PGAP2 null cells, sub-
stantial amounts of CD59 appeared to
localize to a concentrated area character-
istic of Golgi localization (Figure S3B).
Indeed, when the cells were treated with
Brefeldin A, a Golgi-disrupting chemical,
CD59 exhibited a more diffusive localiza-tion pattern (Figure S3B). These data indicate that incomplete
GPI anchor modification can result in intracellular retention of
certain GPI-APs.
Together, these results demonstrate that, although critical to
certain GPI-APs, the PIGN and PGAP2-conferred GPI modifica-
tions are not universal requirements for GPI-AP pathways. Our
findings also indicate that the composition of the GPI anchor
can significantly influence the trafficking of GPI-APs in a sub-
strate-dependent manner.
SEC62 and SEC63 Selectively Regulate a Subset
of GPI-APs
Next, we focused on the functional roles of SEC62 and SEC63,
which were recovered in the PrP screen but not in the CD59
screen. SEC62 and SEC63 are poorly characterized molecules
thought to regulate signal recognition particle (SRP)-indepen-
dent protein translocation into the ER (Lang et al., 2012; Lakkar-
aju et al., 2012; Mades et al., 2012). SEC63 has been shown to
be required for the biosynthesis of subsets of membrane and
secreted proteins, including PrP (Lang et al., 2012; Lakkaraju
et al., 2012). In yeasts, both Sec62p and Sec63p are thought
to regulate the entire family of GPI-APs (Ast et al., 2013), which
follow a SRP-independent route of ER targeting. However, PrP
has been well established as a co-translational substrate in
mammalian cells (Kim and Hegde, 2002). It is unclear whether
PrP’s dependence on both SEC62 and SEC63 in mammalian
cells is because PrP belongs to the class of GPI-APs or whether
it is the result of protein-specific features. We used CRISPR/
Cas9 to delete the SEC62 or SEC63 gene in HAP1 cells (Fig-
ure S4A). We observed that the surface expression of PrP
was strongly reduced in SEC62 or SEC63 null cells, whereas
the CD59 surface expression remained unchanged (Figures
5A and 5B), confirming the findings of the haploid genetic
screens.
Sec62p and Sec63p are thought to regulate the entire family of
GPI-APs in yeasts (Ast et al., 2013). However, our genetic
screens indicate that this conclusion does not apply to human
AB
C
Figure 5. SEC62 and SEC63 Are Required for the PrP Pathway but Are Dispensable for the Biogenesis of CD59, CD55, and CD109
(A)SEC62,SEC63, orPRNPwas deleted fromHAP1 cells by pX330-basedCRISPR/Cas9, and individual knockout clones were isolated. The surface levels of PrP
in the indicated cells were measured by flow cytometry.
(B) Surface levels of the indicated GPI-APs in WT and mutant HAP1 cells were measured by flow cytometry. To rescue gene expression, plasmids encoding
SEC62 or SEC63 were transiently transfected into the knockout cells.
(C) SEC62 or SEC63 was deleted from the diploid HCT116 cells by pX330-based CRISPR/Cas9. Surface levels of the indicated GPI-APs in the pooled knockout
cells were measured by flow cytometry.cells. To further investigate the roles of SEC62 and SEC63 in hu-
man cells, we examined the surface expression of CD55 and
CD109. We observed that CD55 and CD109 were expressed
normally on the cell surface in SEC62 or SEC63 null HAP1 cells,
indicating that their biogenesis is also independent of SEC62 and
SEC63 (Figure 5B). We then characterized the functions of
SEC62 and SEC63 in HCT116 cells, a diploid human cell line
(Mueller et al., 2000). Similar to the results in HAP1 cells, the sur-
face expression of PrP, but not CD59 or CD55, was compro-
mised in SEC62 or SEC63 null HCT116 cells (Figure 5C), indi-
cating that our conclusions are not limited to haploid cells.
Our data demonstrate that, of all the GPI-APs examined in this
study, PrP is the only one dependent on SEC62 and SEC63.
Thus, rather than being universal for GPI-AP trafficking, the
requirement of the SEC62-SEC63 pathway is restricted to a
small subset of GPI-APs in human cells. Thus, mammalian
GPI-AP pathways have diverged from their yeast counterpartsCeand exhibit both SEC62-SEC63-dependent and -independent
mechanisms for ER targeting.
The Signal Sequence of PrP Dictates the Choice
between ER Targeting and Cytosolic Degradation
Next, we sought to further characterize SEC62 and SEC63 in PrP
biogenesis. It has been postulated that the requirement for the
SEC62-SEC63 pathway is dependent on the intrinsic property
of a signal sequence (Ng et al., 1996). If a signal sequence cannot
be efficiently recognized by SRP, it is thought to engage the
SEC62-SEC63 pathway for ER targeting (Kim and Hegde,
2002; Kim et al., 2002; Levine et al., 2005; Drisaldi et al., 2003;
Orsi et al., 2006). Direct evidence for this possibility, however,
is still lacking.
To assess the ER targeting and translocation of PrP, we took
advantage of post-translational modifications that indicate dis-
tinct stages of its maturation (Figures 6A and 6B) (Emermanll Reports 11, 1727–1736, June 23, 2015 ª2015 The Authors 1731
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Figure 6. The Signal Sequence of PrP Dictates the Choice between ER Targeting and Cytosolic Degradation
(A) Diagrams showing WT and mutant PrP proteins used in this study with key domains indicated. Red dots indicate the position of an HA tag in an unstructured
domain of PrP. SS, signal sequence; HD, hydrophobic domain; GPI, C-terminal GPI-conjugating sequence.
(B) Immunoblots showing the expression of WT and mutant PrP proteins. Plasmids encoding the indicated proteins were transiently expressed inWT andmutant
HAP1 cells and were detected by immunoblotting using monoclonal anti-HA antibodies. Mutant HAP1 cells deficient in SEC62 or SEC63 were prepared as
described in Figure 5. CHO, the cytosolic/immature form; Mat, the fully glycosylated mature form; Comp, the fully glycosylated complexed form (Kretzschmar
et al., 1986; Emerman et al., 2010).
(C) WT PrP was transiently expressed in WT or mutant HAP1 cells. The cells were treated with 100 nM of the proteasome inhibitor PS-341, 10 mM of the ERAD
inhibitor Eeyarestatin I, or 1 mM of the ERAD inhibitor kifunensine for the indicated periods of time before analysis by immunoblotting.
(D) Model illustrating the dual role of signal sequence in the PrP pathway. InWT cells, the signal sequence is recognized by SEC62-SEC63 and targeted to the ER.
In the absence of SEC62-SEC63, the signal sequence directs PrP to the pQC pathway for degradation.et al., 2010). InSEC62orSEC63 null cells, all forms of PrP proteins
were diminished (Figure 6B), indicating that improperly targeted
PrP proteins were degraded. To examine the functional role of
the signal sequence, we replaced the signal sequence of PrP
with that of prolactin (Prl-PrP; Figure 6A), a secretory protein
known to utilize the SRP-dependent ER targeting pathway (Kurz-
chalia et al., 1986). Strikingly, substitution with the prolactin signal
sequence fully rescued the expression of PrP in SEC62 or SEC63
null cells (Figure 6B).Moreover, Prl-PrPwas properly glycosylated
in SEC62 or SEC63 null cells (Figure 6B), suggesting that both
translocation and maturation were restored by the signal seq-
uence substitution. PrP contains an internal hydrophobic domain
thatmayalso influenceERtargeting (Hegdeetal., 1998).However,
when the hydrophobic domain was deleted, the mutant PrP pro-
tein (DHD-PrP) behaved similarly toWT PrP (Figure 6B). These re-
sults indicate that the engagement of PrP in the SEC62-SEC63
pathway is solely determined by its signal sequence.
We observed that removal of the signal sequence from PrP
(DSS-PrP) selectively stabilized an unglycosylated form of PrP1732 Cell Reports 11, 1727–1736, June 23, 2015 ª2015 The Authors(Figure 6B), indicating that the signal sequence is required for
PrP degradation in the SEC62 or SEC63 null cells. Improperly
targeted membrane proteins can be degraded via two distinct
pathways. First, they can be directly degraded in the cytosol
by the proteasome through a pre-emptive quality control (pQC)
pathway (Kang et al., 2006; Orsi et al., 2006). Alternatively, a sub-
strate may first enter the ER and then be degraded through ER-
associated degradation (ERAD) (Ashok and Hegde, 2008). To
distinguish between these possibilities, we treated the cells
with the proteasome inhibitor PS-341. We observed that PS-
341 treatment strongly stabilized the cytosolic form of PrP in
SEC62 or SEC63 null cells. PS-341 also moderately increased
the levels of the cytosolic species of PrP in WT cells (Figure 6C),
consistent with the notion that a fraction of PrP is naturally mis-
targeted and degraded in the cytosol (Rane et al., 2004). Next we
inhibited ERAD using Eeyarestatin I, an inhibitor of the p97
ATPase (Wang et al., 2008) and kifunensine, an inhibitor of
alpha-mannosidase (Elbein et al., 1990; Tokunaga et al., 2000).
In contrast to PS-341, neither Eeyarestatin I nor kifunensine
stabilized any form of PrP (Figure 6C), indicating that PrP was not
targeted to the ER prior to degradation. In agreement with this
finding, PS-341 did not stabilize the ER-localized species of
PrP (Figure 6C). Thus, in SEC62 or SEC63 null cells, PrP is
degraded mainly by the cytosolic pQC pathway.
In SEC62 or SEC63 null cells, small amounts of PrP proteins
remained (Figure 6B). These remaining proteins appeared to
be properly glycosylated (Figure 6B). Indeed, they were fully
resistant to endoglycosidase H (Endo H) treatment (Figure S4B),
indicating that these proteins had acquiredmature glycosylation.
These data are in agreement with the notion that PrP also en-
gages in the SRP-dependent ER targeting pathway (Rane
et al., 2008). The vast majority of PrP molecules, however, are
dependent on the SEC62-SEC63 pathway for targeting to the
ER membrane.
Together, these results demonstrate that the signal sequence
determines the engagement of PrP in the SEC62-SEC63 ER tar-
geting pathway. When the SEC62-SEC63 pathway is blocked,
the same signal sequence directs PrP to the cytosolic pQC
pathway for degradation.
DISCUSSION
Our comparative haploid genetic screens provide comprehen-
sive views of the biogenesis and trafficking pathways of PrP
and CD59, two molecules that have attracted substantial atten-
tion due to their disease implications. The PrP and CD59 path-
ways share many common components, most of which are
known to be involved in the synthesis of the GPI anchor. The
most interesting insights, however, came from the specialized
factors identified only in one GPI-AP pathway but not in the
other. The recovery of these specialized factors is unexpected
because all GPI-APs are thought to follow similar biosynthetic
and trafficking routes (Tokunaga et al., 2014). After all, despite
their diverse functions, GPI-APs are similarly tethered to the exo-
plasmic face of the plasma membrane.
Three of the specialized factors we recovered are GPI-modi-
fying enzymes encoded by PIGN, PGAP2, and PIGF. The
PIGN-encoded enzyme catalyzes the addition of EtNP side chain
to the first alpha 1,4-linked mannose of the GPI anchor. The
enzyme encoded by PGAP2, on the other hand, is required for
re-acylation at the sn2 positionwith a saturated acyl chain, which
likely plays a role in stabilizing CD59 at the cell surface (Hong
et al., 1999). PIGF is required for the stabilization of another
EtNP transferase known as PIGO (Inoue et al., 1993; Shishioh
et al., 2005), which adds EtNP to the third mannose of the GPI
anchor. The recovery of these three genes in the CD59 screen
but not in the PrP screen suggests that GPI-APs exhibit markedly
distinct sensitivity to alterations in the GPI anchor. These data
are also consistent with the findings of a previous study using
a chemical inhibitor of PIGN (Hong et al., 1999). Thus, theGPI an-
chor does not act as a passive tether for GPI-APs. Instead, its
composition can significantly influence the biogenesis and sta-
bility of GPI-APs in a substrate-dependent manner.
Another two specialized factors—SEC62 and SEC63—were
recovered only in the PrP screen but not in the CD59 screen.
Yeast studies suggested that the SEC62-SEC63 ER targeting
pathway is the universal route for GPI-APs (Ast et al., 2013).CeHowever, of all the mammalian GPI-APs we examined, only
PrP is dependent on the SEC62-SEC63 pathway, suggesting
that SEC62 and SEC63 only regulate a small subset of mamma-
lian GPI-APs. Thus, we conclude that the requirement for
SEC62-SEC63 is determined on an individual protein basis,
instead of including the entire class of GPI-APs.
We discovered that the engagement in the SEC62-SEC63
pathway is solely determined by the N-terminal signal sequence
of PrP. In yeasts, GPI-APs appear to possess weak signal se-
quences that may direct them to the SRP-independent ER tar-
geting pathway (Ast et al., 2013). However, the signal sequences
of human PrP, CD59, and CD109 are very similar in both length
and hydrophobicity (Figure S5), suggesting that signal sequence
strength alone cannot account for the engagement in the
SEC62-SEC63 ER targeting pathway. Instead, the ER targeting
mechanism is likely determined by an intrinsic property of each
signal sequence, dependent on not only the length and hydro-
phobicity but also composition and location of the sequence.
We further showed that the signal sequence plays dual role in
the PrP pathway. In WT cells, the signal sequence directs the
PrP protein to the SEC62-SEC63 ER targeting pathway. In the
absence of SEC62-SEC63, the signal sequence directs PrP to
the cytosolic pQC pathway for degradation, consistent with the
notion that the prolonged exposure of any unchaperoned hydro-
phobic sequence in the cytosol can target mislocalized proteins
to the proteasome for degradation (Hessa et al., 2011). Thus, it is
the dynamic competition of ER targeting and cytosolic pQC that
determines the outcome of PrP biogenesis. We expect that this
mechanism represents a common feature for other SEC62-
SEC63-dependent substrates.
Finally, our screens identified SPPL3 in the CD59 pathway.
Like signal peptide peptidase (SPP), SPPL3 is an aspartyl intra-
membrane cleaving protease (I-CLiP). SPPL3 is evolutionarily
conserved, but its physiological importance remains unknown
(Voss et al., 2013). The identification of SPPL3 in the CD59
pathway suggests that SPPL3 plays important roles in mem-
brane protein biogenesis, and its function cannot be substituted
by other SPP or SPP-like proteases.
Together, these results suggest that GPI-APs can follow diver-
gent biosynthetic and trafficking pathways in spite of their simi-
larity in overall architecture and subcellular localization. In addi-
tion to providing insights into GPI-AP pathways, our results also
demonstrate that comparative haploid genetics constitutes a
powerful platform for systematic dissection of membrane path-
ways. Haploid genetic screens present two key advantages.
First, the expression of a gene is fully eliminated when the
gene-trap retroviral insertion occurs in the exons or early introns
of the gene. Second, gene-trap insertions can be precisely map-
ped to the human genome such that haploid genetics does not
suffer the off-target effects observed in RNAi or CRISPR/Cas9.
Like in other genetic systems, redundant or essential genes
are not recovered in haploid genetic screens. For example, no
molecular chaperones or vesicle budding/fusion regulators
were recovered in our screens although they are known to be
essential to membrane trafficking pathways (Bonifacino and
Glick, 2004). Nevertheless, our findings pave the way for further
interrogating these pathways through complementary ap-
proaches such as biochemical reconstitution. Recently, severalll Reports 11, 1727–1736, June 23, 2015 ª2015 The Authors 1733
haploid pluripotent stem cells were isolated (Leeb and Wutz,
2011; Li et al., 2012; Yang et al., 2012; Elling et al., 2011). Since
pluripotent stem cells can be programmed into various cell
types, haploid genetic screens can be performed to investigate
cell-type-specific pathways. Altogether, these haploid genetic
systems will likely play important roles in uncovering novel fea-
tures of mammalian membrane biology.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
HAP1 cells were cultured in Iscove’s modified Dulbecco’s medium (IMDM;
Hyclone, #SH30380) supplemented with 10% fetal bovine serum (FBS;
Sigma-Aldrich, #F2442) and penicillin/streptomycin (Sigma-Aldrich, #P4333).
The 293T cells (ATCC, #CRL-3216) were grown in DMEM (Sigma-Aldrich,
#D5671) supplemented with 20% FBS. HCT116 cells were cultured in
DMEM supplementedwith 10%FBS and penicillin/streptomycin. We obtained
Brefeldin A from Sigma-Aldrich (#B7651), Eeyarestatin I from Tocris Biosci-
ence (#3922), Kifunensine from Enzo Life Sciences (#BML-S114), and PS-
341 from LC laboratories (# NC9669075). Endo H (#P0702S) and PNGase F
(#P0704S) were both obtained from New England BioLabs.
Generation of the Mutant HAP1 Cell Library
We generated the mutant HAP1 cell library using a previously described pro-
cedure with minor modifications (Carette et al., 2009). In brief, gene-trap retro-
viruses were produced by transfecting six T175 flasks of 293T cells with a
cocktail of plasmids, including pGT-GFP0, pGT-GFP1, pGT-GFP2, pAdVAnt-
age (Promega, #E1711), pGAL, and pCMV-VSVG using TurboFectin (Origene,
#TF81001). The viruses were collected 40 and 50 hr after transfection and
concentrated in a Beckman SW 28 rotor at 25,000 RPM for 1.5 hr. Viral pellets
were resuspended in 200 ml PBS overnight at 4C. HAP1 cells (1.53 108) were
spin infected in the presence of 8 mg/ml protamine sulfate at two 12-hr intervals
in 12-well plates. Cells were plated at 1.5 3 106 cells per well with 1.53 viral
concentrate (by flask surface area) and centrifuged at 900 g for 1.5 hr at
room temperature in a Thermo Legend RT+ centrifuge. The MOI was kept at
1.0 or lower based on GFP fluorescence.
FACS
HAP1 cells were detached from culture flasks using Accutase (Innovative Cell
Technologies, #AT 104) to preserve surface antigens and labeled with anti-PrP
(eBiosciences, #14-9230) or anti-CD59 (eBiosciences, #17-0596) antibodies
followed by incubation with allophycocyanin (APC)-conjugated anti-mouse
secondary antibodies (eBiosciences, #17-4015). The labeled cells were sorted
using aMoFlo cell sorter (Beckman Coulter), and the data were analyzed using
the FlowJo software.
Deep Sequencing of Retroviral Gene-Trap Insertion
Genomic DNA was extracted from HAP1 cells using a QIAamp DNA Mini Kit
(QIAGEN, #51304). Linear PCR was performed using 2 mg of genomic DNA
as template and the following primer: 50-Biotin-GGTCTCCAAATCTCGGTG
GAAC-30. After 125 cycles of amplification, the linear PCR products were puri-
fied using Dynabeads (M280 Biotin Binder; Life Technologies, #11047). On-
bead ligation of a 50phosphorylated, 30 ddC linker was performed usingCircli-
gase II (Epicenter, #CL9021K). Theproductwaspurified andusedasa template
for PCR to add Illumina adaptor sequences I (50-AATGATACGGCGACCACC
GAGATCTGATGGTTCTCTAGCTTGCC-30) and II (50-CAAGCAGAAGACGG
CATACGA-30). PCR products from six individual PCR reactions were pooled
with a QIAGEN Spin column and sequenced by the Illumina HiSeq 2000
sequencing system using a custom primer recognizing the 50 end of the LTR
(50-CTAGCTTGCCAAACCTACAGGTGGGGTCTTTCA-30).
Bioinformatic Analysis of Retroviral Gene-Trap Insertions
FASTQ files were preprocessed to filter duplicate reads using custom
scripts. FASTQ files containing unique sequences were aligned to the human
genome (hg19) using Bowtie software v.0.12.08 (Langmead et al., 2009). The1734 Cell Reports 11, 1727–1736, June 23, 2015 ª2015 The Authors50 bp FASTQ sequences were trimmed from their 30 ends to a length of
35 bp and were aligned in ‘‘–best mode’’ allowing one mismatch. Reads
with more than one genomic alignment were suppressed. Aligned se-
quences were intersected with gene tables obtained from the UCSC
genome browser containing either exons or introns using BEDTools software
v.2.17.0 (Quinlan and Hall, 2010). Unique insertions per gene were counted
for exons and for introns. The total numbers of sense and antisense inser-
tions within introns were counted for each gene. For Fisher’s exact test,
we used a published control (Carette et al., 2011a), as well as a homemade
control, with no differences observed in results. The heatmap was generated
by normalizing unique insertion counts per gene using the quantile method in
R. Normalized values were used as input for heatmap.2 (package ‘‘gplots’’)
run in R. We developed custom scripts in Python using NumPy, Pandas,
SciPy, and matplotlib modules for downstream data analysis, statistics,
and visualization.
Genome Editing Using CRISPR/Cas9
To prepare CRISPR/Ca9 genome-editing constructs, guide sequences were
designed according to previously published protocols (Ran et al., 2013). The
following guide sequences were used in this study with protospacer adjacent
motifs (PAMs) underlined: PIGP: 50-TACAGTACTTTACCTCGTGTGGG-30,
PIGN: 50-GGTCATGTAGCTCTGATAGCTGG-30, PGAP2: 50-TGGTGAAGCGG
AGCCGTACCAGG-30, SEC62:50-CCACCAATATGAGGGTCACCGG-30, and
SEC63: 50-TCCATTCTTCTTATAGTCTATGG-30.
Double-stranded oligonucleotides containing the guide sequences were
subcloned into the pX330 or pLentiCRISPR vectors (Ran et al., 2013). To knock
out a gene using the pX330 vector, CRISPR/Cas9 plasmids were transiently
transfected into HAP1 or HCT116 cells alongwith pRetroSuper-Puro (OligoEn-
gine, #VEC-PRT-0002) at 1:1 ratio using Fugene HD (Promega, #E2311). On
the following day, the cells were selected with 1 mg/ml puromycin for 2 days
before the cells were harvested for downstream analysis. To delete a gene us-
ing the pLentiCRISPR vector, we used 293T cells to generate viruses using the
same packaging plasmids used to produce gene-trap viruses. The viruses
were concentrated as described above, and target cells were spin infected
with 1.5–2.03 viral titer according to plate surface area. Two days following
infection, the cells were treatedwith 1 mg/ml puromycin for at least 1week prior
to downstream analysis.
In gene rescue experiments, plasmids encoding the genes were obtained
from the Functional Genomics Facility at the University of Colorado Cancer
Center and transiently transfected into the cells using Fugene HD. These plas-
mids were originally generated by the Center for Cancer Systems Biology
(Yang et al., 2011).
Immunoblotting
Cells grown in 24-well plates were lysed in SDS sample buffer, and the sam-
ples were resolved on 8% Bis-Tris SDS-PAGE. Endogenous SEC62 and
SEC63 were detected using rabbit polyclonal anti-SEC62 antibodies
(Sigma-Aldrich, #SAB1303608) and mouse polyclonal anti-SEC63 antibodies
(Sigma-Aldrich, #SAB1407122), respectively. CD59 was detected using rab-
bit polyclonal anti-CD59 antibodies (Abcam, #ab69084). Plasmids express-
ing HA-tagged PrP proteins were previously described (Hegde et al.,
1998; Kim and Hegde, 2002; Rane et al., 2004; Chakrabarti and Hegde,
2009). Transiently expressed PrP proteins were probed using mouse mono-
clonal anti-HA antibodies (Covance/BioLegend, #MMS-101P). Monoclonal
anti-a-tubulin (#14-4502-82) and anti-vinculin (#14-9777-80) antibodies
were both obtained from eBiosciences. Horseradish peroxidase-conjugated
secondary antibodies were obtained from Sigma-Aldrich (#A6154 and
A6782).
Immunostaining
Cells were fixed by 4% paraformaldehyde (Sigma-Aldrich, #P6148) and per-
meabilized using PBS containing 0.1% Triton X-100 (Fisher, #BP151). After
blocking with 10% BSA (Fisher, #BP1600), CD59 was stained using rabbit
polyclonal anti-CD59 antibodies (Abcam, #ab69084) and goat Alexa Fluor
488-conjugated secondary antibodies (Life Technologies, #A-11008). Images
were acquired on a Carl Zeiss 3i Marianas spinning disk confocal microscope
and processed using ImageJ.
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